Umberto Malapelle

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/8718416/umberto-malapelle-publications-by-year.pdf

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

217
papers

3,582
citations

46
g-index

4,932
ext. papers

4,932
ext. citations

4
avg, IF

L-index

#	Paper	IF	Citations
217	Uncommon Compound Mutations in Non-Small Cell Lung Cancer (NSCLC): A Systematic Review of Available Evidence <i>Current Oncology</i> , 2022 , 29, 255-266	2.8	3
216	Tissue Microarray from Cell Block Material (cbTMA) An Additional Shot for Cytology in the Predictive Pathology Era: The PD-L1 Experience. <i>Journal of Molecular Pathology</i> , 2022 , 3, 15-23	0.4	
215	Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario <i>ESMO Open</i> , 2022 , 7, 100406	6	2
214	Predictive molecular pathology in metastatic thyroid cancer: the role of fusions <i>Expert Review of Endocrinology and Metabolism</i> , 2022 , 1-12	4.1	
213	"Depart from evil, and do good": turning Axl from uncontrolled tumorigenic gene to biomarker for early detection of pancreatic cancer <i>Critical Reviews in Oncology/Hematology</i> , 2022 , 103659	7	
212	FFPE-Based NGS Approaches into Clinical Practice: The Limits of Glory from a Pathologist Viewpoint. <i>Journal of Personalized Medicine</i> , 2022 , 12, 750	3.6	0
211	Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies. <i>ESMO Open</i> , 2022 , 7, 10	0459	1
2 10	The challenge of the Molecular Tumor Board empowerment in clinical oncology practice: A Position Paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIC-SIF-SIGU-SIRM Italian Scientific Societies <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 169, 103567	7	13
209	TargetPlex FFPE-Direct DNA Library Preparation Kit for SiRe NGS panel: an international performance evaluation study. <i>Journal of Clinical Pathology</i> , 2021 ,	3.9	4
208	Next generation diagnostic algorithm in non-small cell lung cancer predictive molecular pathology: The KWAY Italian multicenter cost evaluation study. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 169, 103525	7	12
207	The storm of NGS in NSCLC diagnostic-therapeutic pathway: How to sun the real clinical practice. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 169, 103561	7	3
206	p.G12C KRAS mutation prevalence in non-small cell lung cancer: Contribution from interregional variability and population substructures among Hispanics. <i>Translational Oncology</i> , 2021 , 15, 101276	4.9	1
205	Epidermal growth factor receptor exon 20 insertion variants in non-small cell lung cancer patients. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 169, 103536	7	O
204	Immunotherapy in Lung Cancer: Are the Promises of Long-Term Benefit Finally Met?. <i>Advances in Experimental Medicine and Biology</i> , 2021 , 1342, 113-142	3.6	1
203	Liquid Biopsy. UNIPA Springer Series, 2021 , 99-122	0.1	
202	Molecular Diagnostics: Innovative Technologies for Clinical and Translational Research. <i>UNIPA Springer Series</i> , 2021 , 137-151	0.1	
201	EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment. <i>Nature Reviews Clinical Oncology</i> , 2021 ,	19.4	16

(2021-2021)

200	Reliability and reproducibility among different platforms for tumour BRCA testing in ovarian cancer: a study of the Italian NGS Network. <i>Journal of Clinical Pathology</i> , 2021 , 74, 668-672	3.9	1
199	Moving towards a local testing solution for undetermined thyroid fine-needle aspirates: validation of a novel custom DNA-based NGS panel. <i>Journal of Clinical Pathology</i> , 2021 ,	3.9	1
198	Performance evaluation of a fully closed real-time PCR platform for the detection of KRAS p.G12C mutations in liquid biopsy of patients with non-small cell lung cancer. <i>Journal of Clinical Pathology</i> , 2021 ,	3.9	1
197	Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	9
196	RAS as a positive predictive biomarker: focus on lung and colorectal cancer patients. <i>European Journal of Cancer</i> , 2021 , 146, 74-83	7.5	8
195	The evolving landscape of biomarker testing for non-small cell lung cancer in Europe. <i>Lung Cancer</i> , 2021 , 154, 161-175	5.9	24
194	Small Cell Lung Cancer: State of the Art of the Molecular and Genetic Landscape and Novel Perspective. <i>Cancers</i> , 2021 , 13,	6.6	4
193	Next generation sequencing in cytology. <i>Cytopathology</i> , 2021 , 32, 588-595	1.3	6
192	Cytopathology Practice in the COVID-19 Era: Focus on Sample Workload. <i>Journal of Molecular Pathology</i> , 2021 , 2, 109-113	0.4	1
191	Evaluation of a fully closed real time PCR platform for the detection of SARS-CoV-2 in nasopharyngeal swabs: a pilot study. <i>Journal of Clinical Pathology</i> , 2021 ,	3.9	2
190	Dealing with NSCLC EGFR mutation testing and treatment: A comprehensive review with an Italian real-world perspective. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 160, 103300	7	1
189	PD-L1 and beyond: Immuno-oncology in cytopathology. <i>Cytopathology</i> , 2021 , 32, 596-603	1.3	2
188	Immunotherapy in non-small cell lung cancer harbouring driver mutations. <i>Cancer Treatment Reviews</i> , 2021 , 96, 102179	14.4	17
187	Next generation sequencing for liquid biopsy based testing in non-small cell lung cancer in 2021. Critical Reviews in Oncology/Hematology, 2021, 161, 103311	7	7
186	The molecular profiling of solid tumors by liquid biopsy: a position paper of the AIOM-SIAPEC-IAP-SIBioC-SIC-SIF Italian Scientific Societies. <i>ESMO Open</i> , 2021 , 6, 100164	6	38
185	Intensive multidisciplinary treatment strategies and patient resilience to challenge long-term survival in metastatic colorectal cancer: a case report in real life and clinical practice. <i>Annals of Translational Medicine</i> , 2021 , 9, 1027	3.2	O
184	The prognostic impact of tumor mutational burden (TMB) in the first-line management of advanced non-oncogene addicted non-small-cell lung cancer (NSCLC): a systematic review and meta-analysis of randomized controlled trials. <i>ESMO Open</i> , 2021 , 6, 100124	6	31
183	Immunotherapy in Breast Cancer Patients: A Focus on the Use of the Currently Available Biomarkers in Oncology. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2021 ,	2.2	5

182	Liquid Biopsy Analysis in Clinical Practice: Focus on Lung Cancer. <i>Journal of Molecular Pathology</i> , 2021 , 2, 241-254	0.4	3
181	Diagnostic and prognostic biomarkers in oligometastatic non-small cell lung cancer: a literature review. <i>Translational Lung Cancer Research</i> , 2021 , 10, 3385-3400	4.4	O
180	Circulating tumor DNA in cancer: Predictive molecular pathology meets mathematics. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 163, 103394	7	1
179	Cytology in the time of coronavirus disease (COVID-19): an Italian perspective. <i>Journal of Clinical Pathology</i> , 2021 , 74, 261-263	3.9	34
178	Predictive molecular pathology in the time of COVID-19. <i>Journal of Clinical Pathology</i> , 2021 , 74, 234-237	73.9	8
177	Thyroid cytology smear slides: An untapped resource for ThyroSeq testing. <i>Cancer Cytopathology</i> , 2021 , 129, 33-42	3.9	9
176	Thyroid fine-needle aspiration trends before, during, and after the lockdown: what we have learned so far from the COVID-19 pandemic. <i>Endocrine</i> , 2021 , 71, 20-25	4	8
175	RNA-Based Assay for Next-Generation Sequencing of Clinically Relevant Gene Fusions in Non-Small Cell Lung Cancer. <i>Cancers</i> , 2021 , 13,	6.6	6
174	Cytopathology practice during the COVID-19 postlockdown: An Italian experience. <i>Cancer Cytopathology</i> , 2021 , 129, 548-554	3.9	3
173	The Role of the Pathologist in the Next-Generation Era of Tumor Molecular Characterization. <i>Diagnostics</i> , 2021 , 11,	3.8	12
172	Next Generation Sequencing in Cytopathology: Focus on Non-Small Cell Lung Cancer. <i>Frontiers in Medicine</i> , 2021 , 8, 633923	4.9	7
171	Mutations as a Molecular Target for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer. <i>Frontiers in Oncology</i> , 2021 , 11, 644737	5.3	18
170	Liquid Biopsy Is a Promising Tool for Genetic Testing in Idiopathic Pulmonary Fibrosis. <i>Diagnostics</i> , 2021 , 11,	3.8	2
169	Evaluation of Micro Satellite Instability and Mismatch Repair Status in Different Solid Tumors: A Multicenter Analysis in a Real World Setting. <i>Cells</i> , 2021 , 10,	7.9	4
168	The role of molecular heterogeneity targeting resistance mechanisms to lung cancer therapies. <i>Expert Review of Molecular Diagnostics</i> , 2021 , 21, 757-766	3.8	1
167	Benefits and Harms of Lung Cancer Screening by Chest Computed Tomography: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2021 , 39, 2574-2585	2.2	3
166	ctDNA analysis in the personalized clinical management of gastroesophageal adenocarcinoma: turning hope into reality. <i>Future Oncology</i> , 2021 , 17, 4607-4618	3.6	0
165	Liquid Biopsy for Biomarker Testing in Non-Small Cell Lung Cancer: A European Perspective. Journal of Molecular Pathology, 2021 , 2, 255-273	0.4	3

(2020-2021)

164	Methods for actionable gene fusion detection in lung cancer: now and in the future. <i>Pharmacogenomics</i> , 2021 , 22, 833-847	2.6	О	
163	Reference standards for gene fusion molecular assays on cytological samples: an international validation study. <i>Journal of Clinical Pathology</i> , 2021 ,	3.9	2	
162	Liquid biopsy from research to clinical practice: focus on non-small cell lung cancer. <i>Expert Review of Molecular Diagnostics</i> , 2021 , 21, 1165-1178	3.8	2	
161	The tumor-agnostic treatment for patients with solid tumors: a position paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIF Italian Scientific Societies. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 165, 103436	7	28	
160	Evidence-based diagnostic performance of novel biomarkers for the diagnosis of malignant mesothelioma in effusion cytology. <i>Cancer Cytopathology</i> , 2021 ,	3.9	4	
159	How clinically useful is comprehensive genomic profiling for patients with non-small cell lung cancer? A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 166, 103459	7	1	
158	Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 1647-1662	8.9	48	
157	PD-L1 evaluation in head and neck squamous cell carcinoma: Insights regarding specimens, heterogeneity and therapy. <i>Pathology Research and Practice</i> , 2021 , 226, 153605	3.4	5	
156	Molecular profiling of advanced non-small cell lung cancer in the era of immunotherapy approach: a multicenter Italian observational prospective study of biomarker screening in daily clinical practice. Journal of Clinical Pathology, 2021,	3.9	1	
155	Tumor mutational burden on cytological samples: A pilot study. Cancer Cytopathology, 2021 , 129, 460-4	4 67 .9	22	
154	Fine-Needle Aspiration Is Suitable for Breast Cancer BRCA Molecular Assessment: A Case Report. Journal of Molecular Pathology, 2021 , 2, 319-324	0.4		
153	A narrative review of lung cancer cytology in the times of coronavirus: what physicians should know. <i>Translational Lung Cancer Research</i> , 2020 , 9, 2074-2081	4.4	2	
152	Harmonization of Next-Generation Sequencing Procedure in Italian Laboratories: A Multi-Institutional Evaluation of the SiRe Panel. <i>Frontiers in Oncology</i> , 2020 , 10, 236	5.3	5	
151	A BRAF new world. Critical Reviews in Oncology/Hematology, 2020, 152, 103008	7	18	
150	Clinical Multigene Panel Sequencing Identifies Distinct Mutational Association Patterns in Metastatic Colorectal Cancer. <i>Frontiers in Oncology</i> , 2020 , 10, 560	5.3	7	
149	Alterations and Their Role in Cancer Management: Are We Making Headway on Precision Medicine?. <i>Genes</i> , 2020 , 11,	4.2	26	
148	Digital Pathology and PD-L1 Testing in Non Small Cell Lung Cancer: A Workshop Record. <i>Cancers</i> , 2020 , 12,	6.6	5	
147	Comparison between two different next generation sequencing platforms for clinical relevant gene mutation test in solid tumours. <i>Journal of Clinical Pathology</i> , 2020 , 73, 602-604	3.9		

146	The significance of epidermal growth factor receptor uncommon mutations in non-small cell lung cancer: A systematic review and critical appraisal. <i>Cancer Treatment Reviews</i> , 2020 , 85, 101994	14.4	51
145	Targeting emerging molecular alterations in the treatment of non-small cell lung cancer: current challenges and the way forward. <i>Expert Opinion on Investigational Drugs</i> , 2020 , 29, 363-372	5.9	8
144	Pharmacodynamics of current and emerging PD-1 and PD-L1 inhibitors for the treatment of non-small cell lung cancer. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020 , 16, 87-96	5.5	3
143	PD-L1 expression in cell-blocks of non-small cell lung cancer: The impact of prolonged fixation. <i>Diagnostic Cytopathology</i> , 2020 , 48, 595-603	1.4	5
142	Cytology meets next generation sequencing and liquid biopsy: A case of lung adenocarcinoma presenting as metastasis to the phalanx. <i>Diagnostic Cytopathology</i> , 2020 , 48, 759-764	1.4	2
141	Next generation sequencing identifies novel potential actionable mutations for grade I meningioma treatment. <i>Histology and Histopathology</i> , 2020 , 35, 741-749	1.4	4
140	Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB). <i>Critical Reviews in Oncology/Hematology</i> , 2020 , 151, 102978	7	39
139	Rapid On-site Molecular Evaluation in thyroid cytopathology: A same-day cytological and molecular diagnosis. <i>Diagnostic Cytopathology</i> , 2020 , 48, 300-307	1.4	11
138	Treatment of advanced non-small-cell lung cancer: The 2019 AIOM (Italian Association of Medical Oncology) clinical practice guidelines. <i>Critical Reviews in Oncology/Hematology</i> , 2020 , 146, 102858	7	28
137	Evaluation of BRAF, RAS, RET/PTC, and PAX8/PPARg alterations in different Bethesda diagnostic categories: A multicentric prospective study on the validity of the 7-gene panel test in 1172 thyroid FNAs deriving from different hospitals in South Italy. <i>Cancer Cytopathology</i> , 2020 , 128, 107-118	3.9	26
136	Understanding EGFR heterogeneity in lung cancer. ESMO Open, 2020, 5, e000919	6	17
135	SARS-CoV-2 Infection in Cancer Patients: A Picture of an Italian Unit. Frontiers in Oncology, 2020 , 10, 17	23 .3	3
134	Precision Prevention and Cancer Interception: The New Challenges of Liquid Biopsy. <i>Cancer Discovery</i> , 2020 , 10, 1635-1644	24.4	21
133	BRAF as a positive predictive biomarker: Focus on lung cancer and melanoma patients. <i>Critical Reviews in Oncology/Hematology</i> , 2020 , 156, 103118	7	9
132	Concomitant Rare KRAS and BRAF Mutations in Lung Adenocarcinoma: A Case Report. <i>Journal of Molecular Pathology</i> , 2020 , 1, 36-42	0.4	О
131	BRAF: A Two-Faced Janus. <i>Cells</i> , 2020 , 9,	7.9	10
130	Case Report: BAP1 Mutation and RAD21 Amplification as Predictive Biomarkers to PARP Inhibitor in Metastatic Intrahepatic Cholangiocarcinoma. <i>Frontiers in Oncology</i> , 2020 , 10, 567289	5.3	3
129	Liquid biopsy for mutations testing in non-small cell lung cancer: a retrospective study. <i>Journal of Clinical Pathology</i> , 2020 ,	3.9	5

(2019-2020)

128	mutations testing in non-small cell lung cancer: the role of Liquid biopsy in the basal setting. <i>Journal of Thoracic Disease</i> , 2020 , 12, 3836-3843	2.6	29
127	KRAS inhibition in non-small cell lung cancer: Past failures, new findings and upcoming challenges. <i>European Journal of Cancer</i> , 2020 , 137, 57-68	7.5	18
126	Global impact of the COVID-19 pandemic on cytopathology practice: Results from an international survey of laboratories in 23 countries. <i>Cancer Cytopathology</i> , 2020 , 128, 885-894	3.9	16
125	Molecular predictive testing in precision oncology: The Italian experience. <i>Cancer Cytopathology</i> , 2020 , 128, 622-628	3.9	1
124	Impact of Pre-Analytical Factors on MSI Test Accuracy in Mucinous Colorectal Adenocarcinoma: A Multi-Assay Concordance Study. <i>Cells</i> , 2020 , 9,	7.9	7
123	Predictive molecular pathology in the time of coronavirus disease (COVID-19) in Europe. <i>Journal of Clinical Pathology</i> , 2020 ,	3.9	12
122	Mismatch repair proteins and microsatellite instability in solid pseudopapillary neoplasm of the pancreas. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2019 , 18, 491-492	2.1	
121	The Reproducibility of the Immunohistochemical PD-L1 Testing in Non-Small-Cell Lung Cancer: A Multicentric Italian Experience. <i>BioMed Research International</i> , 2019 , 2019, 6832909	3	15
120	A Simplified Genomic Profiling Approach Predicts Outcome in Metastatic Colorectal Cancer. <i>Cancers</i> , 2019 , 11,	6.6	8
119	Emerging angiogenesis inhibitors for non-small cell lung cancer. <i>Expert Opinion on Emerging Drugs</i> , 2019 , 24, 71-81	3.7	9
118	Intensive first-line FIr-C/FOx-C association of triplet chemotherapy plus cetuximab in wild-type metastatic colorectal cancer patients: preliminary phase II data and prediction of individual limiting toxicity syndromes by pharmacogenomic biomarkers. <i>Therapeutic Advances in Medical Oncology</i> ,	5.4	7
117	2019 , 11, 1758835919846421 Pathology in non-small cell lung cancer: evolving scenario. <i>Precision Cancer Medicine</i> , 2019 , 2, 17-17	1	
116	Birdß eye view of modern cytopathology: Report from the seventh international Molecular Cytopathology Meeting in Naples, Italy, 2018. <i>Cancer Cytopathology</i> , 2019 , 127, 350-357	3.9	2
115	Is the Idylla Mutation Assay feasible on archival stained cytological smears? A pilot study. <i>Journal of Clinical Pathology</i> , 2019 , 72, 609-614	3.9	11
114	Patients Selection for Immunotherapy in Solid Tumors: Overcome the NaWe Vision of a Single Biomarker. <i>BioMed Research International</i> , 2019 , 2019, 9056417	3	28
113	Consistency and reproducibility of next-generation sequencing in cytopathology: A second worldwide ring trial study on improved cytological molecular reference specimens. <i>Cancer Cytopathology</i> , 2019 , 127, 285-296	3.9	24
112	Next Generation Sequencing and Genetic Alterations in Squamous Cell Lung Carcinoma: Where Are We Today?. <i>Frontiers in Oncology</i> , 2019 , 9, 166	5.3	34
111	BRAF Mutations in Lung Cancer. <i>Acta Cytologica</i> , 2019 , 63, 247-250	3	5

110	PD-L1 expression on routine samples of non-small cell lung cancer: results and critical issues from a 1-year experience of a centralised laboratory. <i>Journal of Clinical Pathology</i> , 2019 , 72, 412-417	3.9	18
109	Microfluidic chip technology applied to fine-needle aspiration cytology samples for IGH clonality assessment. <i>Diagnostic Cytopathology</i> , 2019 , 47, 749-757	1.4	2
108	Class 1, 2, and 3 -Mutated Metastatic Colorectal Cancer: A Detailed Clinical, Pathologic, and Molecular Characterization. <i>Clinical Cancer Research</i> , 2019 , 25, 3954-3961	12.9	36
107	Role of Cytomorphology in the Era of Liquid Biopsy. <i>Acta Cytologica</i> , 2019 , 63, 497-505	3	2
106	The Promise of Digital Biopsy for the Prediction of Tumor Molecular Features and Clinical Outcomes Associated With Immunotherapy. <i>Frontiers in Medicine</i> , 2019 , 6, 172	4.9	25
105	Prognostic Factors and Biomarkers of Responses to Immune Checkpoint Inhibitors in Lung Cancer. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	29
104	Liquid biopsy tracking of lung tumor evolutions over time. <i>Expert Review of Molecular Diagnostics</i> , 2019 , 19, 1099-1108	3.8	34
103	Targeting Immune-Related Biological Processes in Solid Tumors: We do Need Biomarkers. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	33
102	Prospective detection of mutations in cerebrospinal fluid, pleural effusion, and ascites of advanced cancer patients to guide treatment decisions. <i>Molecular Oncology</i> , 2019 , 13, 2633-2645	7.9	45
101	exon 19 deletion switch and development of p.L792Q mutation as a new resistance mechanism to osimertinib: a case report and literature review <i>Translational Cancer Research</i> , 2019 , 8, S64-S69	0.3	9
100	Listening understanding and acting (lung): focus on communicational issue in thoracic oncology <i>Translational Cancer Research</i> , 2019 , 8, S16-S22	0.3	
99	Targeted therapy and non-small cell lung cancer: a new era!. Translational Cancer Research, 2019, 8, S1-	· S2 .3	
98	Opening New Boundaries in Biomarker Detection: Awakening of Middle East and North Africa Region. <i>Journal of Immunotherapy and Precision Oncology</i> , 2019 , 2, 8-9	0.6	
97	Analysis of Programmed Death-Ligand 1 Expression, Stromal Tumor-Infiltrating Lymphocytes, and Mismatch Repair Deficiency in Invasive Micropapillary Carcinoma of the Breast. <i>Journal of Immunotherapy and Precision Oncology</i> , 2019 , 2, 130-136	0.6	1
96	Circulating Tumour Cells in Predictive Molecular Pathology: Focus on Drug-Sensitive Assays and 3D Culture. <i>Acta Cytologica</i> , 2019 , 63, 171-181	3	4
95	T790M detection rate in lung adenocarcinomas at baseline using droplet digital PCR and validation by ultra-deep next generation sequencing. <i>Translational Lung Cancer Research</i> , 2019 , 8, 584-592	4.4	15
94	USP11 role in colorectal cancer growing and metastatisation. <i>EBioMedicine</i> , 2019 , 48, 5-6	8.8	5
93	Liquid Biopsy and Lung Cancer. <i>Acta Cytologica</i> , 2019 , 63, 489-496	3	39

92 Next-Generation Sequencing in Clinical Practice **2019**, 57-64

DNA-Based Sequencing Assays 2019, 83-97 RNA-Based Assays 2019, 99-119 Setting up and exploitation of a nano/technological platform for the evaluation of HMGA1b protein in peripheral blood of cancer patients. Nanomedicine: Nanotechnology, Biology, and Medicine, 2019, 15, 231-242 Performance analysis of SiRe next-generation sequencing panel in diagnostic setting: focus on NSCLC routine samples. Journal of Clinical Pathology, 2019, 72, 38-45 Different qualifiers of AUS/FLUS thyroid FNA have distinct BRAF, RAS, RET/PTC, and PAX8/PPARg alterations. Cancer Cytopathology, 2018, 126, 317-325 Antitumor Efficacy of Dual Blockade of EGFR Signaling by Osimertinib in Combination With Selumetinib or Cetuximab in Activated EGFR Human NCLC Tumor Models. Journal of Thoracic Oncology, 2018, 13, 810-820 Targeting immune checkpoints in non small cell lung cancer. Current Opinion in Pharmacology, 2018, 40, 46-50 Somertinib. Recent Results in Cancer Research, 2018, 211, 257-276 Noninvasive Biomarkers of Colorectal Cancer: Role in Diagnosis and Personalised Treatment Perspectives. Gastroenterology Research and Practice, 2018, 2018, 2397863 Clinico-pathological and molecular characterisation of BRAF mutant metastatic colorectal cancer (mCRC): Are all mutations created equal?. Journal of Clinical Oncology, 2018, 36, 3590-3590	3 25 25 19 36
Setting up and exploitation of a nano/technological platform for the evaluation of HMGA1b protein in peripheral blood of cancer patients. <i>Nanomedicine: Nanotechnology, Biology, and Medicine,</i> 2019, 15, 231-242 88 Performance analysis of SiRe next-generation sequencing panel in diagnostic setting: focus on NSCLC routine samples. <i>Journal of Clinical Pathology,</i> 2019, 72, 38-45 87 Different qualifiers of AUS/FLUS thyroid FNA have distinct BRAF, RAS, RET/PTC, and PAX8/PPAR9 alterations. <i>Cancer Cytopathology,</i> 2018, 126, 317-325 88 Antitumor Efficacy of Dual Blockade of EGFR Signaling by Osimertinib in Combination With Selumetinib or Cetuximab in Activated EGFR Human NCLC Tumor Models. <i>Journal of Thoracic Oncology,</i> 2018, 13, 810-820 89 Targeting immune checkpoints in non small cell lung cancer. <i>Current Opinion in Pharmacology,</i> 2018, 40, 46-50 80 Simertinib. <i>Recent Results in Cancer Research,</i> 2018, 211, 257-276 81 Noninvasive Biomarkers of Colorectal Cancer: Role in Diagnosis and Personalised Treatment Perspectives. <i>Gastroenterology Research and Practice,</i> 2018, 2018, 2397863 Clinico-pathological and molecular characterisation of BRAF mutant metastatic colorectal cancer	25 25 19 36
in peripheral blood of cancer patients. Nanomedicine: Nanotechnology, Biology, and Medicine, 2019, 15, 231-242 Performance analysis of SiRe next-generation sequencing panel in diagnostic setting: focus on NSCLC routine samples. Journal of Clinical Pathology, 2019, 72, 38-45 Different qualifiers of AUS/FLUS thyroid FNA have distinct BRAF, RAS, RET/PTC, and PAX8/PPARg alterations. Cancer Cytopathology, 2018, 126, 317-325 Antitumor Efficacy of Dual Blockade of EGFR Signaling by Osimertinib in Combination With Selumetinib or Cetuximab in Activated EGFR Human NCLC Tumor Models. Journal of Thoracic Oncology, 2018, 13, 810-820 Targeting immune checkpoints in non small cell lung cancer. Current Opinion in Pharmacology, 2018, 40, 46-50 Somertinib. Recent Results in Cancer Research, 2018, 211, 257-276 Noninvasive Biomarkers of Colorectal Cancer: Role in Diagnosis and Personalised Treatment Perspectives. Gastroenterology Research and Practice, 2018, 2018, 2397863 Clinico-pathological and molecular characterisation of BRAF mutant metastatic colorectal cancer	25 25 19 36
NSCLC routine samples. Journal of Clinical Pathology, 2019, 72, 38-45 87 Different qualifiers of AUS/FLUS thyroid FNA have distinct BRAF, RAS, RET/PTC, and PAX8/PPARg alterations. Cancer Cytopathology, 2018, 126, 317-325 3.9 Antitumor Efficacy of Dual Blockade of EGFR Signaling by Osimertinib in Combination With Selumetinib or Cetuximab in Activated EGFR Human NCLC Tumor Models. Journal of Thoracic Oncology, 2018, 13, 810-820 85 Targeting immune checkpoints in non small cell lung cancer. Current Opinion in Pharmacology, 2018, 40, 46-50 84 Osimertinib. Recent Results in Cancer Research, 2018, 211, 257-276 85 Noninvasive Biomarkers of Colorectal Cancer: Role in Diagnosis and Personalised Treatment Perspectives. Gastroenterology Research and Practice, 2018, 2018, 2397863 86 Clinico-pathological and molecular characterisation of BRAF mutant metastatic colorectal cancer	25 19 36
Antitumor Efficacy of Dual Blockade of EGFR Signaling by Osimertinib in Combination With Selumetinib or Cetuximab in Activated EGFR Human NCLC Tumor Models. <i>Journal of Thoracic Oncology</i> , 2018 , 13, 810-820 Targeting immune checkpoints in non small cell lung cancer. <i>Current Opinion in Pharmacology</i> , 2018 , 40, 46-50 Osimertinib. <i>Recent Results in Cancer Research</i> , 2018 , 211, 257-276 Noninvasive Biomarkers of Colorectal Cancer: Role in Diagnosis and Personalised Treatment Perspectives. <i>Gastroenterology Research and Practice</i> , 2018 , 2018, 2397863 Clinico-pathological and molecular characterisation of BRAF mutant metastatic colorectal cancer	19 36
Selumetinib or Cetuximab in Activated EGFR Human NCLC Tumor Models. Journal of Thoracic Oncology, 2018, 13, 810-820 Targeting immune checkpoints in non small cell lung cancer. Current Opinion in Pharmacology, 2018, 40, 46-50 Osimertinib. Recent Results in Cancer Research, 2018, 211, 257-276 Noninvasive Biomarkers of Colorectal Cancer: Role in Diagnosis and Personalised Treatment Perspectives. Gastroenterology Research and Practice, 2018, 2018, 2397863 Clinico-pathological and molecular characterisation of BRAF mutant metastatic colorectal cancer	36
40, 46-50 84 Osimertinib. Recent Results in Cancer Research, 2018, 211, 257-276 83 Noninvasive Biomarkers of Colorectal Cancer: Role in Diagnosis and Personalised Treatment Perspectives. Gastroenterology Research and Practice, 2018, 2018, 2397863 2 Clinico-pathological and molecular characterisation of BRAF mutant metastatic colorectal cancer	
Noninvasive Biomarkers of Colorectal Cancer: Role in Diagnosis and Personalised Treatment Perspectives. <i>Gastroenterology Research and Practice</i> , 2018 , 2018, 2397863 Clinico-pathological and molecular characterisation of BRAF mutant metastatic colorectal cancer	14
Perspectives. Gastroenterology Research and Practice, 2018, 2018, 2397863 Clinico-pathological and molecular characterisation of BRAF mutant metastatic colorectal cancer	,
	43
(4
81 How to Prepare Cytological Samples for Molecular Testing 2018 , 11-28	
Intensive first line FIr-C/FOx-C association of triplet chemotherapy plus cetuximab in RAS wild-type 80 metastatic colorectal cancer patients: Preliminary phase II data and prediction of individual limiting 2.2 toxicity syndromes by pharmacogenomic biomarkers Journal of Clinical Oncology, 2018, 36, e15517-e15517	
An update on liquid biopsy analysis for diagnostic and monitoring applications in non-small cell lung cancer. <i>Expert Review of Molecular Diagnostics</i> , 2018 , 18, 35-45	38
, and mutations detected by next generation sequencing, and differential clinical outcome in metastatic colorectal cancer (MCRC) patients treated with first line FIr-B/FOx adding bevacizumab (BEV) to triplet chemotherapy. <i>Oncotarget</i> , 2018 , 9, 26279-26290	13
Evaluation of a novel liquid biopsy-based ColoScape assay for mutational analysis of colorectal neoplasia and triage of FIT+ patients: a pilot study. <i>Journal of Clinical Pathology</i> , 2018 , 71, 1123-1126	3
Idylla assay and next generation sequencing: an integrated EGFR mutational testing algorithm. Journal of Clinical Pathology, 2018 , 71, 745-750 3.9	23
USP7 inhibitors, downregulating CCDC6, sensitize lung neuroendocrine cancer cells to PARP-inhibitor drugs. <i>Lung Cancer</i> , 2017 , 107, 41-49	

74	Profile of the Roche cobas EGFR mutation test v2 for non-small cell lung cancer. <i>Expert Review of Molecular Diagnostics</i> , 2017 , 17, 209-215	3.8	99
73	Microsatellite instability evaluation by automated microfluidic electrophoresis: an update. <i>Journal of Clinical Pathology</i> , 2017 , 70, 90-91	3.9	9
72	mutation detection on lung cancer cytological specimens by the novel fully automated PCR-based Idylla Mutation Assay. <i>Journal of Clinical Pathology</i> , 2017 , 70, 295-300	3.9	37
71	Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients. <i>British Journal of Cancer</i> , 2017 , 116, 802-810	8.7	93
70	Multiplex digital colour-coded barcode technology on RNA extracted from routine cytological samples of patients with non-small cell lung cancer: pilot study. <i>Journal of Clinical Pathology</i> , 2017 , 70, 803-806	3.9	13
69	There is still a role for cytology in the Riquid biopsyPera. A lesson from a TKI-treated patient showing adenocarcinoma to squamous cell carcinoma transition during disease progression. <i>Journal of Clinical Pathology</i> , 2017 , 70, 798-802	3.9	16
68	P2.01-093 Exo-ALK Proof of Concept: Exosomal Analysis of ALK Alterations in Advanced NSCLC Patients. <i>Journal of Thoracic Oncology</i> , 2017 , 12, S844-S845	8.9	5
67	Consistency and reproducibility of next-generation sequencing and other multigene mutational assays: A worldwide ring trial study on quantitative cytological molecular reference specimens. <i>Cancer Cytopathology</i> , 2017 , 125, 615-626	3.9	43
66	Cell free DNA analysis by SiRe next generation sequencing panel in non small cell lung cancer patients: focus on basal setting. <i>Journal of Thoracic Disease</i> , 2017 , 9, S1383-S1390	2.6	31
65	ALK and ROS1 testing on lung cancer cytologic samples: Perspectives. <i>Cancer Cytopathology</i> , 2017 , 125, 817-830	3.9	34
64	How to prepare cytological samples for molecular testing. Journal of Clinical Pathology, 2017, 70, 819-	.825 9	44
63	miR-155 is positively regulated by CBX7 in mouse embryonic fibroblasts and colon carcinomas, and targets the KRAS oncogene. <i>BMC Cancer</i> , 2017 , 17, 170	4.8	18
62	New perspectives in the second-line treatment of non squamous NSCLC patients: Results from a large Italian Lung Cancer Working Group. <i>Critical Reviews in Oncology/Hematology</i> , 2017 , 109, 35-41	7	12
61	Discordance in RAS mutations between primary colon tumor and metastases: a real event or a matter of methodology?. <i>International Journal of Biological Markers</i> , 2017 , 32, e474-e477	2.8	2
60	The Cause of Death of a Child in the 18th Century Solved by Bone Microbiome Typing Using Laser Microdissection and Next Generation Sequencing. <i>International Journal of Molecular Sciences</i> , 2017 , 18,	6.3	6
59	Liquid biopsy analysis of ALK alterations from advanced NSCLC patients: The value of exosomal RNA cargo (ExoALK) <i>Journal of Clinical Oncology</i> , 2017 , 35, e20569-e20569	2.2	2
58	Parallel sequencing of a 50 genes panel in metastatic colorectal cancer (MCRC) patients (pts) treated with intensive first-line FIr-B/FOx triplet chemotherapy plus bevacizumab (BEV): Preliminary data and clinical outcome <i>Journal of Clinical Oncology</i> , 2017 , 35, 644-644	2.2	1
57	Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR. <i>Oncotarget</i> , 2017 , 8, 23020-23032	3.3	26

56	detection on archival cytological smears by the novel fully automated polymerase chain reaction-based Idylla mutation test. <i>CytoJournal</i> , 2017 , 14, 5	1.1	8
55	Clinical Practice Implications: Monitoring Drug Response and Resistance. <i>Current Clinical Pathology</i> , 2017 , 201-202	0.1	
54	Differential clinical outcome of metastatic colorectal cancer (MCRC) patients (pts) treated with first line FIr-B/FOx adding bevacizumab (BEV) to triplet chemotherapy according to KRAS, NRAS and BRAF genotype detected by massive parallel sequencing <i>Journal of Clinical Oncology</i> , 2017 , 35, e15041	2.2 I-e150	o 41
53	Fully automated PCR detection of KRAS mutations on pancreatic endoscopic ultrasound fine-needle aspirates. <i>Journal of Clinical Pathology</i> , 2016 ,	3.9	26
52	EGFR mutation detection on routine cytological smears of non-small cell lung cancer by digital PCR: a validation study. <i>Journal of Clinical Pathology</i> , 2016 , 69, 454-7	3.9	19
51	UbcH10 overexpression is less pronounced in older colorectal cancer patients. <i>International Journal of Colorectal Disease</i> , 2016 , 31, 1367-8	3	3
50	EGFR mutation detection on lung cancer cytological specimens by the rapid and fully integrated Idylla molecular diagnostics system <i>Journal of Clinical Oncology</i> , 2016 , 34, e20542-e20542	2.2	
49	Fully automated PCR detection of KRAS mutations on pancreatic endoscopic ultrasound fine needle aspirates <i>Journal of Clinical Oncology</i> , 2016 , 34, e15726-e15726	2.2	
48	Next generation sequencing techniques in liquid biopsy: focus on non-small cell lung cancer patients. <i>Translational Lung Cancer Research</i> , 2016 , 5, 505-510	4.4	75
47	UbcH10 expression can predict prognosis and sensitivity to the antineoplastic treatment for colorectal cancer patients. <i>Molecular Carcinogenesis</i> , 2016 , 55, 793-807	5	18
46	Cytopathologists can reliably perform ultrasound-guided thyroid fine needle aspiration: a 1-year audit on 3715 consecutive cases. <i>Cytopathology</i> , 2016 , 27, 115-21	1.3	30
45	Less frequently mutated genes in colorectal cancer: evidences from next-generation sequencing of 653 routine cases. <i>Journal of Clinical Pathology</i> , 2016 , 69, 767-71	3.9	56
44	Young investigator challenge: Can the Ion AmpliSeq Cancer Hotspot Panel v2 be used for next-generation sequencing of thyroid FNA samples?. <i>Cancer Cytopathology</i> , 2016 , 124, 776-784	3.9	16
43	Lung adenocarcinoma and its thyroid metastasis characterized on fine-needle aspirates by cytomorphology, immunocytochemistry, and next-generation sequencing. <i>Diagnostic Cytopathology</i> , 2015 , 43, 585-9	1.4	18
42	SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer. <i>Clinical Cancer Research</i> , 2015 , 21, 4686-97	12.9	93
41	Restoration of CBX7 expression increases the susceptibility of human lung carcinoma cells to irinotecan treatment. <i>Naunyn-Schmiedebergn</i> Archives of Pharmacology, 2015 , 388, 1179-86	3.4	20
40	Performance of EGFR mutant-specific antibodies in different cytological preparations: a validation study. <i>Cytopathology</i> , 2015 , 26, 99-105	1.3	7
39	Outsourcing cytological samples to a referral laboratory for EGFR testing in non-small cell lung cancer: does theory meet practice?. <i>Cytopathology</i> , 2015 , 26, 312-7	1.3	23

38	Ion Torrent next-generation sequencing for routine identification of clinically relevant mutations in colorectal cancer patients. <i>Journal of Clinical Pathology</i> , 2015 , 68, 64-8	3.9	67
37	Fine-needle aspiration findings in focal (nodular) myositis of a newborn: A case report. <i>Diagnostic Cytopathology</i> , 2015 , 43, 920-3	1.4	
36	Cytopathology meets basic science. <i>Cancer Cytopathology</i> , 2015 , 123, 571-2	3.9	1
35	Challenges and opportunities of next-generation sequencing: a cytopathologistB perspective. <i>Cytopathology</i> , 2015 , 26, 271-83	1.3	61
34	EGFR mutant allelic-specific imbalance assessment in routine samples of non-small cell lung cancer. <i>Journal of Clinical Pathology</i> , 2015 , 68, 739-41	3.9	5
33	EGFR testing and the CAP/IASLC/AMP lung cancer biomarker testing guidelines: knowledge gaps and future directions. <i>Lung Cancer Management</i> , 2015 , 4, 87-95	2.6	
32	Next-generation sequencing in the genomic profiling of synchronous colonic carcinomas: comment on Li et al (2015). <i>Journal of Clinical Pathology</i> , 2015 , 68, 946-7	3.9	6
31	KRAS mutant allele-specific imbalance (MASI) assessment in routine samples of patients with metastatic colorectal cancer. <i>Journal of Clinical Pathology</i> , 2015 , 68, 265-9	3.9	11
30	EGFR analysis: current evidence and future directions. <i>Diagnostic Cytopathology</i> , 2014 , 42, 984-92	1.4	32
29	KRAS testing in metastatic colorectal carcinoma: challenges, controversies, breakthroughs and beyond. <i>Journal of Clinical Pathology</i> , 2014 , 67, 1-9	3.9	30
28	Analysis of differential miRNA expression in primary tumor and stroma of colorectal cancer patients. <i>BioMed Research International</i> , 2014 , 2014, 840921	3	46
27	Diffuse large B-cell extranodal lymphoma of the uterine cervix: an incidental pap smear finding with histological and immunohistochemical correlation. <i>Diagnostic Cytopathology</i> , 2014 , 42, 644-6	1.4	6
26	Epidermal growth factor receptor test performed on liquid-based cytology lung samples: experience of an academic referral center. <i>Acta Cytologica</i> , 2014 , 58, 589-94	3	30
25	Applications and limitations of oncogene mutation testing in clinical cytopathology. <i>Seminars in Diagnostic Pathology</i> , 2013 , 30, 284-97	4.3	35
24	UbcH10 overexpression in human lung carcinomas and its correlation with EGFR and p53 mutational status. <i>European Journal of Cancer</i> , 2013 , 49, 1117-26	7.5	20
23	Sphingosine kinase 1 overexpression contributes to cetuximab resistance in human colorectal cancer models. <i>Clinical Cancer Research</i> , 2013 , 19, 138-47	12.9	77
22	EGFR mutations detected on cytology samples by a centralized laboratory reliably predict response to gefitinib in non-small cell lung carcinoma patients. <i>Cancer Cytopathology</i> , 2013 , 121, 552-60	3.9	58
21	Foamy gland pancreatic ductal adenocarcinoma diagnosed on EUS-FNA: a histochemical, immunohistochemical, and molecular report. <i>Diagnostic Cytopathology</i> , 2013 , 41, 77-80	1.4	10

(2010-2013)

20	Warthin tumor with signet-ring cell features as a pitfall in salivary gland cytopathology. <i>Acta Cytologica</i> , 2013 , 57, 309-12	3	2
19	PAX8 is expressed in anaplastic thyroid carcinoma diagnosed by fine-needle aspiration: a study of three cases with histological correlates. <i>European Journal of Endocrinology</i> , 2013 , 169, 307-11	6.5	16
18	EGFR mutation detection by microfluidic technology: a validation study. <i>Journal of Clinical Pathology</i> , 2013 , 66, 982-4	3.9	11
17	Next-generation sequencing of lung cancer EGFR exons 18-21 allows effective molecular diagnosis of small routine samples (cytology and biopsy). <i>PLoS ONE</i> , 2013 , 8, e83607	3.7	67
16	EGFR mutations detection on liquid-based cytology: is microscopy still necessary?. <i>Journal of Clinical Pathology</i> , 2012 , 65, 561-4	3.9	29
15	Cytological and molecular features of papillary thyroid carcinoma with prominent hobnail features: a case report. <i>Acta Cytologica</i> , 2012 , 56, 560-4	3	31
14	Multicentric encapsulated papillary oncocytic neoplasm of the thyroid: A case diagnosed by a combined cytological, histological, immunohistochemical, and molecular approach. <i>Diagnostic Cytopathology</i> , 2012 , 40, 450-4	1.4	9
13	KRAS mutation detection by high-resolution melting analysis significantly predicts clinical benefit of cetuximab in metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2012 , 107, 626-31	8.7	22
12	Immunoglobulin heavy-chain fluorescence in situ hybridization-chromogenic in situ hybridization DNA probe split signal in the clonality assessment of lymphoproliferative processes on cytological samples. <i>Cancer Cytopathology</i> , 2012 , 120, 390-400	3.9	23
11	Sanger sequencing in routine KRAS testing: a review of 1720 cases from a pathologistß perspective. <i>Journal of Clinical Pathology</i> , 2012 , 65, 940-4	3.9	24
10	EGFR and KRAS mutations detection on lung cancer liquid-based cytology: a pilot study. <i>Journal of Clinical Pathology</i> , 2012 , 65, 87-91	3.9	60
9	CBX7 is a tumor suppressor in mice and humans. <i>Journal of Clinical Investigation</i> , 2012 , 122, 612-23	15.9	114
8	Thyroid Carcinoma: Molecular Signature by Histotype-Specific Mutations and Gene Expression Patterns 2012 , 165-178		
7	KRAS testing on colo-rectal carcinoma cytological imprints. <i>Diagnostic Cytopathology</i> , 2011 , 39, 274-7	1.4	9
6	Cytology-based gene mutation tests to predict response to anti-epidermal growth factor receptor therapy: a review. <i>Diagnostic Cytopathology</i> , 2011 , 39, 703-10	1.4	46
5	Preparation of thyroid FNA material for routine cytology and BRAF testing: a validation study. <i>Diagnostic Cytopathology</i> , 2010 , 38, 172-6	1.4	17
4	KRAS mutation analysis on cytological specimens of metastatic colo-rectal cancer. <i>Diagnostic Cytopathology</i> , 2010 , 38, 869-73	1.4	19
3	Metastasis of colon cancer to the thyroid gland: a case diagnosed on fine-needle aspirate by a combined cytological, immunocytochemical, and molecular approach. <i>Diagnostic Cytopathology</i> , 2010 , 38, 932-5	1.4	16

Cyclin D1 and D3 overexpression predicts malignant behavior in thyroid fine-needle aspirates suspicious for Hurthle cell neoplasms. *Cancer Cytopathology*, **2009**, 117, 522-9

3.9 27

Cytological and molecular diagnosis of solid variant of papillary thyroid carcinoma: a case report. *CytoJournal*, **2008**, 5, 2

1.1 17